Mebeverine
Overview
Mebeverine (HCl) is antispasmodic agent with direct action on the smooth muscle of the gastrointestinal tract. It relieves the abdominal pain and cramps. It was first registered in 1965. Mebeverine (HCl) is administered orally.
Categories
- 17 Gastrointestinal drugs
Primary Characterstics
Mebeverine (HCl) is the derivative of MebeverineMebeverine (HCl) is the derivative of Mebeverine It is of Synthetic origin. It belongs to Cholinergic muscarinic antagonist pharmacological group on the basis of mechanism of action and also classified in Gastrointestinal Anticholinergics/Antispasmodics and Antispasmodic Agent pharmacological group.The Molecular Weight of Mebeverine is 466.00.
Its pKa is 8.1.
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Mebeverine's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 135 to 150 mg | 140 (142.5) | 8 hourly | PO | 20 mins before meals, |
Paedriatic Dosage (20kg)
|
| 25 mg | 25 (25) | As recommended. | | For 3-4 years |
| 50 mg | 50 (50) | As recommended. | | For 4-8 years |
| 100 mg | 100 (100) | As recommended. | | For 8-10 years |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Mebeverine is available. |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Mebeverine
Back to top
Previous Drug Generic - Next Drug Generic